Skip to main content
. 2022 Jun 20;29(9):2810–2822. doi: 10.1111/ene.15428

FIGURE 4.

FIGURE 4

Total tau (T‐tau) in plasma in patients with inflammatory polyneuropathies and controls. (a) Absolute concentration of T‐tau in plasma. (b) Log transformed NfL values in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), paraproteinaemic demyelinating neuropathy (PDN), and multifocal motor neuropathy (MMN) vs. controls. (c) Log transformed NfL values in GBS and CIDP patients prior to‐ and following immunomodulatory treatment. ALS, amyotrophic lateral sclerosis; CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain–Barré syndrome; HA, headaches; HC, healthy controls; MMN, multifocal motor neuropathy; NIP, non‐inflammatory polyneuropathy; PDN, paraproteinaemic demyelinating neuropathy. a, pre‐treatment; b, post‐treatment; horizontal lines represent median values. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001